Nautilus Biotechnology to Announce First Quarter 2025 Financial Results on April 29, 2025
Nautilus Biotechnology (NASDAQ: NAUT), a pioneer in single-molecule proteome analysis platform development, has scheduled its first quarter 2025 financial results announcement for Tuesday, April 29, 2025, before market open.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Nautilus Biotechnology (NASDAQ: NAUT), a pioneer in single-molecule proteome analysis platform development, has scheduled its first quarter 2025 financial results announcement for Tuesday, April 29, 2025, before market open. The company will host a conference call and webcast at 5:30 a.m. Pacific Time / 8:30 a.m. Eastern Time to discuss quarterly results, business developments, and future outlook. Investors can access the live audio webcast through the company's website investor section at www.nautilus.bio.
Details
News Market Reaction – NAUT
The recorded move for NAUT in the trading session of this news was -6.08%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SEATTLE, April 16, 2025 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule proteome analysis platform, today announced it will report financial results for the first quarter 2025 before market open on Tuesday, April 29, 2025.
The company’s management will webcast a corresponding conference call beginning at 5:30 a.m. Pacific Time / 8:30 a.m. Eastern Time to discuss its results, business developments, and outlook. Live audio of the webcast will be available on the “Investors” section of the company website at: www.nautilus.bio.
About Nautilus Biotechnology, Inc.
With its corporate headquarters in Seattle, Washington and its research and development headquarters in San Carlos, California, Nautilus is a development stage life sciences company working to create a platform technology for quantifying and unlocking the complexity of the proteome. Nautilus’ mission is to transform the field of proteomics by democratizing access to the proteome and enabling fundamental advancements across human health and medicine. To learn more about Nautilus, visit www.nautilus.bio
Media Contact
press@nautilus.bio
Investor Contact
investorrelations@nautilus.bio
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.